Overview

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Status:
NOT_YET_RECRUITING

Trial end date:
2029-11-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.

Phase:

PHASE2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Dasatinib